Source:Journal of Allergy and Clinical Immunology
Author(s): Frank C. Albers, Robert G. Price, Steven G. Smith, Steven W. Yancey
Teaser
This post hoc analysis of the MENSA study demonstrates that mepolizumab reduced the annualized exacerbation rate relative to placebo in patients with severe eosinophilic asthma irrespective of the number or type of background controller therapies.http://ift.tt/2snaNHK
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου